FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 501–600 of 1,002
Parmar, A., Chaves-Porras, J., Saluja, R., Perry, K., Rahmadian, A. P., Santos, S. D., Ko, Y., Berry, S. R., Doherty, M. K., & Chan, K. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102817 · Cited by 29
Dahdaleh, F. S., Naffouje, S. A., Hanna, M. H., & Salti, G. I. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04581-y · Cited by 29
Coppola, A., Vaccara, V. L., Fiore, M., Farolfi, T., Ramella, S., Angeletti, S., Coppola, R., & Caputo, D. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690580 · Cited by 28
“In this regard, actual 5-year low survival rates of 17% have been reported, with the grade of lymph node involvement proving to be among the main predictors of survival in resected PDACs (8) For these reasons, chemotherapy and chemo-radiation therapy are often proposed in a neoadjuvant setting, aiming to increase the…”
BackgroundGo, S., Lee, S., Bae, W. K., Zang, D. Y., Lee, H. W., Jang, J. S., Ji, J. H., Kim, J. H., Park, S.-G., Sym, S. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.002 · Cited by 28
Merali, N., Chouari, T. A. M., Kayani, K., Rayner, C. J., Jiménez, J. I., Krell, J., Giovannetti, E., Bagwan, I., Relph, K., Rockall, T., et al. (2022) · Cancers · doi:10.3390/cancers14041020 · Cited by 29
Survival and Robotic Approach for Pancreaticoduodenectomy: A Propensity Score-Match Study
Rosemurgy, A. S., Ross, S. B., Espeut, A., Nguyen, D., Crespo, K., Syblis, C., Vasanthakumar, P., & Sucandy, I. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000137 · Cited by 28
The circadian clock is disrupted in pancreatic cancer
Schwartz, P. B., Nukaya, M., Berres, M. E., Rubinstein, C. D., Wu, G., Hogenesch, J. B., Bradfield, C. A., & Ronnekleiv‐Kelly, S. M. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010770 · Cited by 32
“rather than local tumor growth, and so examining the contribution of clock disruption to overall survival 534 was of greater importance.(65) We found that Bmal1 mutation promoted earlier metastatic spread of tumors 535 resulting in earlier lethality, which has not been shown before.”
BackgroundZhang, Y., Kong, R., Yang, W., Hu, K., Zhao, Z., Li, L., Geng, X., Liu, L., Chen, H., Xiao, P., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216288 · Cited by 32
Loosen, S. H., Tacke, F., Puethe, N., Binnebösel, M., Wiltberger, G. J., Alizai, P. H., Kather, J. N., Paffenholz, P., Ritz, T., Koch, A. H., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz033 · Cited by 28
Sanford, N. N., Aguilera, T. A., Folkert, M. R., Ahn, C. W., Mahal, B. A. V., Zeh, H. J., Beg, M. S., Mansour, J. C., & Sher, D. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7322 · Cited by 28
Chong, E., Ratnayake, B., Dasari, B. V. M., Loveday, B. P. T., Siriwardena, A. K., & Pandanaboyana, S. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-06309-8 · Cited by 30
Markowski, A., Jaromin, A., Migdał, P., Olczak, E., Zygmunt, A., Zaremba-Czogalla, M., Pawlik, K., & Gubernator, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105536 · Cited by 32
“Unfortunately, the vast majority of patients with PDAC are diagnosed at the final stages of the disease, with the predicted average lifespan of 6 months for gemcitabine-treated patients and up to 11 months for those patients who can overcome the strong side effects of FOLFIRINOX therapy [14,15].”
BackgroundWei, A. C.-C., Ou, F., Shi, Q., Carrero, X. W., O'Reilly, E. M., Meyerhardt, J. A., Wolff, R. A., Kindler, H. L., Evans, D. B., Deshpande, V., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07685-1 · Cited by 27
Self-citationTramontano, A. C., Chen, Y., Watson, T. R., Eckel, A. L., Sheehan, D. F., Peters, M. L. B., Pandharipande, P. V., Hur, C., & Kong, C. Y. (2019) · Medicine · doi:10.1097/md.0000000000018082 · Cited by 27
Kamarajah, S. K., Bundred, J., Alrawashdeh, W., Manas, D., & White, S. A. (2019) · HPB · doi:10.1016/j.hpb.2019.12.001 · Cited by 30
Jones, C. M., Radhakrishna, G., Aitken, K. L., Bridgewater, J. A., Corrie, P. G., Eatock, M. M., Goody, R. B., Ghaneh, P., Good, J. S., Grose, D. B., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0980-x · Cited by 29
“In the absence of adjuvant chemotherapy, five year survival for patients who have undergone resection is less than 10%, compared with over 20% for those who receive adjuvant treatment.(26-29) For example, in a recent randomized controlled trial, adjuvant FOLFIRINOX delivered 3-year disease-free survival of 39.”
BackgroundSinn, M., Liersch, T., Riess, H. B., Gellert, K., Stübs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W. O., Bitzer, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.032 · Cited by 27
Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021
Turpin, A., Amrani, M. E., Bachet, J., Pietrasz, D., Schwarz, L., & Hammel, P. R. (2020) · Cancers · doi:10.3390/cancers12123866 · Cited by 26
“[9], grade 3–4 adverse events were reported in 75.”
BackgroundSelf-citationZakem, S., Mueller, A. C., Meguid, C. L., Torphy, R. J., Holt, D. E., Schefter, T. E., Messersmith, W. A., McCarter, M. D., Chiaro, M. D., Schulick, R. D., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.11.004 · Cited by 27
Hanna-Sawires, R. G., Schiphuis, J. H., Wuhrer, M., Vasen, H. F. A., van Leerdam, M. E., Bonsing, B. A., Mesker, W. E., van der Burgt, Y. E. M., & Tollenaar, R. A. �. �. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052655 · Cited by 30
“The 5-year survival rate for this group of patients is estimated at 10% [27].”
BackgroundHoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103327 · Cited by 29
“One might question the role of Gemcitabine in curable PDAC as mFOLFIRNOX showed superiority in terms of longer DFS and OS as compared to gemcitabine alone in R0-resected PDAC patients recently [35].”
ResultMilan, M., Diaferia, G. R., & Natoli, G. (2021) · The EMBO Journal · doi:10.15252/embj.2020107206 · Cited by 28
“…chemotherapy such as FOLFIR-INOX (fluorouracil, irinotecan, oxaliplatin, and leucovorin) that significantly improves survival of PDAC patients compared with standard monotherapy with gemcitabine (Conroy et al, 2018) is unable to efficiently eradicate undifferentiated tumors (Aung et al, 2018).”
van der Sijde, F., Homs, M. Y. V., van Bekkum, M. L., van den Bosch, T. P. P., Bosscha, K. P., Besselink, M. G., Bonsing, B. A., de Groot, J. W. B., Karsten, T. M., Koerkamp, B. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010902 · Cited by 27
“First-line FOLFIRINOX prolongs survival of advanced PDAC patients [3,4] as well as survival in patients with resectable or borderline resectable disease when administered as adjuvant treatment [5].”
BackgroundBansod, S., Dodhiawala, P. B., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13215481 · Cited by 31
Seufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1856-7346 · Cited by 34
Hydroxychavicol as a potential anticancer agent (Review)
Mohamad, N. S., Rahman, A. A., & Kadir, S. H. S. A. (2022) · Oncology Letters · doi:10.3892/ol.2022.13620 · Cited by 33
“…and fluorouracil, known as FOLFIRINOX, is also used due to its efficacy and ability to promote significantly longer survival than gemcitabine (63). unfortunately, ~80% of cases of pancreatic cancer progress into metastatic cancers with the development of liver metastases within 2 years of…”
A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy
Li, W., Gonzalez-Gonzalez, M., Sanz-Criado, L., Garcia-Carbonero, N., Celdrán, Á., Villarejo‐Campos, P., Mínguez, P., Pazo-Cid, R., García‐Jiménez, C., Orta, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247310 · Cited by 29
Hong, E., Barczak, W., Park, S., Heo, J. S., Ooshima, A., Munro, S., Hong, C. P., Park, J., An, H., Park, J. O., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05630-5 · Cited by 31
for the Dutch Pancreatic Cancer Group, Mackay, T. M., Smits, F. J., Latenstein, A. E. J., Bogte, A., Bonsing, B. A., Bos, H., Bosscha, K. P., Brosens, L. A. A., Hol, L., et al. (2020) · Trials · doi:10.1186/s13063-020-4180-z · Cited by 29
Zhu, J., Zhang, K., Chen, Y., Ge, X., Wu, J., Xu, P., & Yao, J. J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05307-3 · Cited by 34
“HIF-1α promotes transcriptional activation in a variety of ways, including activating metabolic switches that promote glycolysis and the expression of various proangiogenic cytokines, including VEGF-A, which acts on surrounding endothelial cells to induce the formation of new blood vessels [79].”
BackgroundHabib, J. R., Kinny‐Köster, B., Javed, A. A., Zelga, P., Saadat, L. V., Kim, R. C., Gorris, M., Allegrini, V., Watanabe, S., Sharib, J. M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02313 · Cited by 33
“31,32 12-14 Herein, we leveraged the international”
Heckler, M., Polychronidis, G., Kinny‐Köster, B., Roth, S., Hank, T. P., Kaiser, J., Michalski, C. W., & Loos, M. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.10.007 · Cited by 32
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 35
Levêque, D., & Becker, G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1662395 · Cited by 27
Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
Sasaki, T., Fujiwara‐Tani, R., Kishi, S., Mori, S., Luo, Y., Ohmori, H., Kawahara, I., Goto, K., Nishiguchi, Y., Mori, T., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2547 · Cited by 26
Watson, M. D., Miller-Ocuin, J. L., Driedger, M. R., Beckman, M. J., McKillop, I. H., Baker, E. H., Martinie, J. B., Vrochides, D. V., Iannitti, D. A., & Ocuin, L. M. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0011 · Cited by 26
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2475 · Cited by 28
Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
Sugawara, T., Ban, D., Nishino, J., Watanabe, S., Maekawa, A., Ishikawa, Y., Akahoshi, K., Ogawa, K., Ono, H., Kudo, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249885 · Cited by 30
Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
Curtain, B. M. M., Quirke, N., Thorpe, S. D., & Gallagher, T. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122711 · Cited by 32
AlMasri, S. S., Zenati, M. S., DeSilva, A., Nassour, I., Boone, B. A., Singhi, A. D., Bartlett, D. L., Liotta, L. A., Espina, V. A., Loughran, P., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4211 · Cited by 30
Heumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 28
Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
Manrai, M., Tilak, T., Dawra, S., Srivastava, S., & Singh, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6572 · Cited by 26
Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer
Ostios-García, L., Villamayor, J., Garcia-Lorenzo, E., Viñal, D., & Feliú, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6775 · Cited by 29
Iacobazzi, R. M., Arduino, I., Fonte, R., Lopedota, A., Serratì, S., Racaniello, G. F., Bruno, V., Laquintana, V., Lee, B. C., Silvestris, N., et al. (2021) · Cancers · doi:10.3390/cancers14010005 · Cited by 27
“Although the FOLFIRINOX regimen has been confirmed to be superior to Gem for the treatment of PDAC, the higher toxicity of such a treatment limits its application [9].”
BackgroundHill, C., Rosati, L. M., Hu, C., Fu, W., Sehgal, S., Hacker‐Prietz, A., Wolfgang, C. L., Weiss, M. J., Burkhart, R. A., Hruban, R. H., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11202-8 · Cited by 26
Slapak, E. J., el Mandili, M., Bijlsma, M. F., & Spek, C. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020390 · Cited by 28
Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer
Sivapalan, L., Thorn, G. J., Gadaleta, E., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09387-6 · Cited by 28
Yan, B., Liu, L., Zhao, L., Hinz, U., Luo, Y., An, X., Gladkich, J., Torre, C. D. L., Huang, Z., Schrapel, D., et al. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.11.002 · Cited by 27
Ecker, B. L., Tao, A. J., Janssen, Q. P., Walch, H. S., Court, C. M., Balachandran, V. P., Crane, C. H., D'Angelica, M. I., Drebin, J. A., Kingham, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3089 · Cited by 30
Self-citationRamaekers, M., Viviers, C. G. A., Janssen, B. V., Hellström, T. A. E., Ewals, L. J. S., van der Wulp, K., Nederend, J., Jacobs, I., Pluyter, J. R., Mavroeidis, D., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134209 · Cited by 30
“Although pancreatic cancer treatment has improved over the past years through centralization and optimization of treatment strategies, overall survival has not significantly improved [3,4].”
BackgroundWang, S., Chen, J., Li, P., & Chen, Y. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06311-z · Cited by 26
A narrative review of genetic factors affecting fluoropyrimidine toxicity
Gmeiner, W. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-17 · Cited by 25
“However, its use was associated with higher incidence of toxic effects (23), demonstrating the need to better understand and manage toxicities related to FP use.”
BackgroundStein‐Thoeringer, C. K., Renz, B. W., de Castilhos, J., von Ehrlich-Treuenstätt, V., Wirth, U., Tschaidse, T., Hofmann, F. O., Koch, D. T., Beirith, I., Ormanns, S., et al. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006210 · Cited by 31
Poyia, F., Neophytou, C. M., Christodoulou, M., & Papageorgis, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179555 · Cited by 33
“The 5-year disease-free survival rate was 26.1% for FOLFIRINOX-treated patients and 19.0% for gemcitabine [19].”
BackgroundInfluentialRong, Z., Xu, J., Jianhui, Y., Wang, W., Tang, R., Zhang, Z.-F., Tan, Z., Meng, Q., Hua, J., Liu, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3596 · Cited by 30
Liaki, V., Barrambana, S., Kostopoulou, M., Lechuga, C. G., Zamorano-Domínguez, E., Acosta, D., Morales-Cacho, L., Álvarez, R., Sun, P., Rosas-Pérez, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523039122 · Cited by 37
RetractedAdjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives
Mas, L., Schwarz, L., & Bachet, J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000639 · Cited by 27
“status of which.[15-17,22,24,25] Most of these factors have subsequently been validated.”
BackgroundMethodInfluentialSelf-citationEndo, Y., Fujimoto, M., Ito, N., Takahashi, Y., Kitago, M., Gotoh, M., Hiraoka, N., Yoshida, T., Kitagawa, Y., Kanai, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03541-6 · Cited by 25
Safi, S. A., Häberle, L., Fluegen, G., Lehwald, N., Krieg, A. H., Keitel, V., Luedde, T., Esposito, I., Rehders, A., & Knoefel, W. T. (2021) · Pancreatology · doi:10.1016/j.pan.2021.02.024 · Cited by 25
“Heterogeneous studies, lack of standardized pathological reporting systems, as well as frequently altered adjuvant treatment regimens over the past decades may have contributed to this effect [6,8 e 10].”
Auclin, É., Marthey, L., Abdallah, R., Mas, L., François, É., Saint, A., Cunha, A. S., Vienot, A., Lecomte, T., Hautefeuille, V., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01341-w · Cited by 25
Self-citationJia, Y., Li, H., Wang, Y., Wang, J., Zhu, J., Wei, Y., Lu, L., Chen, X., & Mo, S. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60018 · Cited by 26
“Despite considerable progress concerning therapeutic approaches has been achieved in the past decades, PDAC remains a lethal disease with 5 year disease-free survival rates of less than 6% after initial diagnosis [2].”
BackgroundLi, R., He, Y., Zhang, H., Wang, J., Liu, X., Liu, H., Wu, H., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690056 · Cited by 29
Role of human nucleoside transporters in pancreatic cancer and chemoresistance
Carter, C. J., Mekkawy, A. H., & Morris, D. L. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6844 · Cited by 26
The impact of nutritional status on pancreatic cancer therapy
Capurso, G., Pecorelli, N., Burini, A., Orsi, G., Palumbo, D., Macchini, M., Mele, R., COBELLI, F. D., Falconi, M., Arcidiacono, P. G., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2026771 · Cited by 26
Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, K. (2021) · Pancreatology · doi:10.1016/j.pan.2021.05.004 · Cited by 29
Shin, D. W., Kim, S., Jung, K., Jung, J. H., Kim, B., Ahn, J., Kim, J., Hwang, J., & Lee, J.-C. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.10.001 · Cited by 28
Lin, H., Yang, P., Li, B., Chang, Y., Chen, Y., Li, Y., Liu, K., Liang, X., Chen, T., Dai, Y., et al. (2022) · Cancers · doi:10.3390/cancers15010202 · Cited by 26
“It is attributed to the diagnosis at advanced stages in most PDAC patients and the high recurrence rate after resection, as well as the resistance to drug therapy [3,4].”
BackgroundGuarneri, G., Pecorelli, N., Bettinelli, A., Campisi, A., Palumbo, D., Genova, L., Gasparini, G., Provinciali, L., Corte, A. D., Abati, M., et al. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.02.005 · Cited by 32
Gunawardana, V. W. L., Ward, C. R., Wang, H., Holbrook, J. H., Sekera, E. R., Cui, H., Hummon, A. B., & Badjić, J. D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306722 · Cited by 24
Ejlsmark, M. W., Bahij, R., Schytte, T., Hansen, C. R., Bertelsen, A. S., Mahmood, F., Mortensen, M. B., Detlefsen, S., Weber, B., Bernchou, U., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110347 · Cited by 28
Nimgaonkar, V. U., Krishna, V., Krishna, V., Tiu, E., Joshi, A., Vrabac, D., Bhambhvani, H. P., Smith, K., Johansen, J. S., Makawita, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101013 · Cited by 29
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Palmer, D. H., Jackson, R., Springfeld, C., Ghaneh, P., Rawcliffe, C. L., Halloran, C. M., Faluyi, O. O., Cunningham, D., Wadsley, J., Darby, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01118 · Cited by 52
“13,14 mFOLFIRINOX however is associated with greater toxicity than GemCap, and the PRODIGE24 trial required more stringent selection criteria, notably patients age 79 years or younger, with a WHO performance status of 0 or 1, no signi fi cant cardio-vascular disease, and a postoperative serum tumor…”
Self-citationChemotherapy and radiotherapy for advanced pancreatic cancer
Haggstrom, L., Chan, W. Y., Nagrial, A. M., Chantrill, L. A., Sim, H., Yip, D., & Chin, V. T. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011044.pub3 · Cited by 52
Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism
Punnasseril, J. M. J., Auwal, A., Gopalan, V., Lam, A. K.-Y., & Islam, F. (2025) · Cancer Medicine · doi:10.1002/cam4.71244 · Cited by 32
Pancreatic cancer in young adults: changes, challenges, and solutions
Primavesi, F., Stättner, S., Schlick, K., Kiesslich, T., Mayr, C., Klieser, E., Urbas, R., & Neureiter, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s176700 · Cited by 29
Okabe, H., Yamashita, Y., Inoue, R., Kinoshita, S., Itoyama, R., Yusa, T., Nakao, Y., Yamao, T., Umezaki, N., Tsukamoto, M., et al. (2019) · Surgery Today · doi:10.1007/s00595-019-01866-x · Cited by 24
Response to Preoperative Therapy in Localized Pancreatic Cancer
Perri, G., Prakash, L. R., & Katz, M. H. G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00516 · Cited by 25
“Systemic therapy following resection improves survival outcomes relative to surgery alone (3), but with the advent of more effective chemotherapy regimens over recent years, efforts have focused on optimizing the administration of chemotherapy and/or (chemo)radiation prior to, instead of following, resection of the pr…”
BackgroundThe Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Čierniková, S., Novisedláková, M., Cholujová, D., Števurková, V., & Mego, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120565 · Cited by 24
Otsuka, T., Shirakawa, T., Shimokawa, M., Koga, F., Kawaguchi, Y., Ueda, Y., Nakazawa, J., Komori, A., Otsu, S., Arima, S., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01859-2 · Cited by 23
Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0021 · Cited by 24
Yoneda, A., Minomi, K., & Tamura, Y. (2021) · Cancer Science · doi:10.1111/cas.14976 · Cited by 25
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Arru, C., Miglio, M. R. D., Cossu, A., Muroni, M. R., Carru, C., Zinellu, A., & Paliogiannis, P. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01796-6 · Cited by 26
Advances in the management of pancreatic ductal adenocarcinoma
O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450 · Cited by 26
What do surgeons need to know about the mesopancreas
Fernandes, E. D. S. M., Strobel, O., Girão, C. L., Moraes-Junior, J. M. A., & Torres, O. J. M. (2021) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02211-y · Cited by 29
Orsi, G., Marco, M. D., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I. G., Garajová, I., Tortora, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100238 · Cited by 24
“Age at diagnosis (years), median (range) 60 (34-84) 61 (34-84) 61 (34-84) Sex, n (%) Female 46 (54) 39 (53) 44 (53) Male 39 (46) 35 (47) 39 (47) ECOG PS at diagnosis, n (%) 0 57 (67) 47 (63) 55 (66) 1 24 (28) 23 (31) 24 (29) 2 4 (5) 4 (6) 4 (5) Clinical stage at diagnosis, n (%) I 7 (8) 5 (7) 7 (8) II 11 (13) 10 (13)…”
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
Moati, É., Taly, V., Garinet, S., Didelot, A., Taïeb, J., Laurent‐Puig, P., & Zaanan, A. (2021) · Cancers · doi:10.3390/cancers13194743 · Cited by 26
Ishido, K., Kimura, N., Wakiya, T., Nagase, H., Hara, Y., Kanda, T., Fujita, H., & Hakamada, K. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10866-6 · Cited by 24
Barrak, D., Villano, A. M., Villafañe-Ferriol, N., Stockton, L. G., Hill, M. V., Deng, M., Handorf, E. A., & Reddy, S. S. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.12.473 · Cited by 24
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
Springfeld, C., & Neoptolemos, J. P. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00612-6 · Cited by 25
B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma
Minici, C., Testoni, S. G. G., & Della‐Torre, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867902 · Cited by 25
“Aside from palliative care or surgery in eligible patients, current treatment options are based on DNA-damaging agents but still offer a life expectancy of less than 40% at three years (5).”
BackgroundPreoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy
Seo, Y. D., & Katz, M. H. G. (2022) · Cancer · doi:10.1002/cncr.34273 · Cited by 26
“This assumption belies our ever- maturing understanding of the underlying biologic features of PDAC.”
BackgroundInfluentialNeoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
Usón, P. L. S., Carvalho, L., Fernandes, M. L. C., Botrus, G., Martins, R. D. S., da Silva, E. F., dos Santos, S. S. M. B., Taniwaki, L., Taranto, P., Dutra, A. C. P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17743-6 · Cited by 25
Zhang, B., Yuan, Q., Zhang, B., Li, S., Wang, Z., Liu, H., Meng, F., Chen, X., & Shang, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1078424 · Cited by 27
Calheiros, J., Corbo, V., & Saraiva, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188914 · Cited by 30
National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer
Nassour, I., Parrish, A., Baptist, L., Voskamp, S., Handoo, K., Rogers, S. C., Fabregas, J. C., George, T. J., Hitchcock, K. E., Paniccia, A., et al. (2023) · HPB · doi:10.1016/j.hpb.2023.06.018 · Cited by 26
Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Jain, A. J., Maxwell, J. E., Katz, M. H. G., & Snyder, R. A. (2023) · Cancers · doi:10.3390/cancers15164174 · Cited by 27
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma
Wattenberg, M. M., Colby, S., Garrido‐Laguna, I., Xue, Y., Chang, R. B., Delman, D., Lee, J., Affolter, K. E., Mulvihill, S. J., Beg, M. S., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.013 · Cited by 24
Chen, Y., Callichurn, K., Chatterjee, A., Désilets, É., Fergal, D., Forbes, N., Gan, S. I., Kenshil, S., Khashab, M. A., Kunda, R., et al. (2019) · Trials · doi:10.1186/s13063-019-3918-y · Cited by 24
Loosen, S. H., Breuer, A., Tacke, F., Kather, J. N., Gorgulho, J., Alizai, P. H., Bednarsch, J., Roeth, A. A., Lurje, G., Schmitz, S. M., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100080 · Cited by 24
Xiang, M. H., Heestand, G. M., Chang, D. T., & Pollom, E. L. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.01.007 · Cited by 25
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.